The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What is the clinical impact of DDX41 mutations in myeloid neoplasms?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Yasushi Miyazaki, Nagasaki University, Nagasaki, JP. We asked, What is the clinical impact of DDX41 mutations in myeloid neoplasms?

What is the clinical impact of DDX41 mutations in myeloid neoplasms?

DDX41 is a gene encoding an RNA helicase called DEAD-box RNA helicase 41. Here, Miyazaki discusses the results of an international study evaluating the clinical impacts of germline and somatic DDX41 mutations on the risk of developing myeloid neoplasms.

 

Share: